Gilead Sciences (GILD) Tops Q2 EPS by 44c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/8/2026
- Wall Street ends lower, off record highs, as Treasury yields climb
- Want to be a stock market bear? BCA says watch potential U.S. tax increases
- SpaceX seeks $40bn in financing for Nvidia chip purchase
- Chip stock could soar nearly 200%, analyst says: "If you don’t buy it, they will"
- Musk rules out TSMC role in Terafab operations; Intel gains
- Anthropic launches Claude Haiku 5.5 with tiered pricing structure
- Sportradar to sell Synergy Sports coaching unit for $170M
- Rezolve AI (RZLV) Reiterated at Overweight by Cantor Fitzgerald on Positioning as Key Component in E-Commerce Stack
- Wall Street ends lower, off record highs, as Treasury yields climb
- Applied Digital (APLD) Tops Q1 EPS by 26c, Beats on Revenue
Gilead Sciences' (GILD) Price Target Bumped to $135 at Deutsche Bank
July 29, 2015 10:13 AM EDTDeutsche Bank maintained a Buy rating on Gilead Sciences (NASDAQ: GILD) and raised its price target to $135.00 (from $125.00). Analyst Robyn Karnauskas characterized Q2 results as "solid" and said HCV discounts don't look bad.
"We are lowering our US HCV revenues while increasing OUS numbers & model WW revs at $18.5B vs.... More
Gilead Sciences (GILD) PT Raised to $134 at Piper Jaffray on Another 'Beat and Raise'
July 29, 2015 9:10 AM EDTPiper Jaffray analyst Joshua Schimmer reiterated an Overweight rating and boosted his price target on Gilead Sciences (NASDAQ: GILD) to $134.00 (from $131.00) following another 'beat and raise'.
Schimmer commented, "GILD hosted its 2Q earnings call after the close and again easily beat consensus product... More
Gilead Sciences (GILD) PT Lifted to $135 at Baird on Strong Earnings Beat
July 29, 2015 6:58 AM EDTBaird analyst Brian Skorney lifted his price target on Outperform-rated Gilead Sciences (NASDAQ: GILD) to $135.00 (from $126.00) following earnings beat.
Skorney commented, "Gilead handily beat expectations, across the board, and raised revenue guidance yet again. Interestingly, nothing in Hep C declined... More
Gilead Sciences (GILD) PT Raised to $120 at Oppenheimer on Solid Q2 Beat
July 29, 2015 6:28 AM EDTOppenheimer analyst Wendy Lam reiterated an Outperform rating and boosted her price target on Gilead Sciences (NASDAQ: GILD) to $120.00 (from $86.00) following solid the Q2 beat.
Lam commented, "GILD reported a healthy 2Q15 EPS and product revenues beat ($3.15/$8.13B vs. $2.71/$7.60B consensus) underpinned by... More
Gilead Sciences (GILD) Declares $0.43 Quarterly Dividend; 1.5% Yield
July 28, 2015 5:18 PM EDTGilead Sciences (NASDAQ: GILD) declared a quarterly dividend of $0.43 per share, or $1.72 annualized.
The dividend will be payable on September 29, 2015, to stockholders of record on September 16, 2015, with an ex-dividend date of September 14, 2015.
The annual yield on the dividend is 1.5... More



